For years, polycystic ovary syndrome (PCOS) support have focused narrowly on the ovary, but a growing scientific consensus suggests this understanding may be too narrow.
In May 2026, experts proposed renaming PCOS to Poly-Endocrine Metabolic Ovary Syndrome (PMOS), reflecting a broader reality: this is not simply a reproductive issue, but a condition involving endocrine balance, metabolic regulation, hormonal signaling, and long-term ovarian health.1
At first glance, the change may seem semantic. In practice, it forces a much larger question: if PCOS is being redefined, should the women’s health market be redefined as well?
Why current PCOS support is missing the bigger picture
One of the biggest misconceptions about PCOS comes from the name itself. When people hear “polycystic ovary”, many assume the condition is caused by ovarian cysts. In fact, the small structures seen on ultrasound are usually not pathological cysts at all. They are immature follicles whose development has stalled due to endocrine and metabolic disruption.
Rather than being the root cause, the ovary is often a downstream target of systemic dysfunction. This distinction matters because many women with polycystic ovarian morphology have normal endocrine and metabolic profiles and may not develop clinical symptoms. Simply treating the ovary misses the larger picture.
At its core, PMOS reflects dysregulation across the hypothalamic-pituitary-ovarian (HPO) axis, insulin signaling, androgen balance, and reproductive physiology. Hormonal dysregulation, ovulatory dysfunction, and fertility challenges are often symptoms of a broader endocrine-metabolic imbalance rather than isolated ovarian pathology.
That shift in perspective matters for both research and business. The next generation of women’s hormonal health solutions cannot focus only on restoring menstrual cycles or ovulation; they must address the underlying drivers of hormonal instability.
Beyond the ovary: Four problems the PMOS era must solve
1. Insulin resistance: The foundation of women’s metabolic health
Among all PMOS-related mechanisms, insulin resistance remains the best understood and one of the most commercially mature.
For many women, impaired insulin sensitivity contributes to weight gain, abdominal fat accumulation, disrupted ovulation, menstrual irregularities, and amplified androgen signaling. This is why nutritional strategies over the past decade have centered on metabolic support.2
Ingredients such as myo-inositol, D-chiro-inositol, berberine, cinnamon extract, and magnesium have become standard tools for improving insulin sensitivity and supporting fertility. In many ways, the market has become highly effective at serving metabolic PMOS. But insulin resistance is only one part of the story.
2. Hyperandrogenism: The root cause behind PCOS acne and hair loss
For consumers, symptoms of PCOS such as acne, oily skin, unwanted hair growth, and PCOS-related hair loss often affect emotional wellbeing more than biomarkers.
Yet products can still address these symptoms indirectly: improve metabolism → reduce insulin burden → lower androgen activity. The limitation becomes clear in women with pronounced androgen symptoms, lean PMOS, or non-insulin-resistant phenotypes, where metabolic interventions alone can produce disappointing results. This makes hyperandrogenism one of the largest unmet needs in women’s hormonal health.
3. Hormonal rhythm dysregulation: The overlooked layer
Not every woman with PMOS struggles primarily with metabolism. Some struggle with rhythm.
Healthy endocrine systems rely on coordinated hormonal timing between the brain, pituitary gland, and ovaries.3 In PMOS, this rhythm can become disrupted, leading to elevated luteinizing hormone (LH), imbalanced LH/FSH signaling, irregular ovulation, and unstable estrogen-progesterone patterns.4
Many of these women are not overweight and may even present normal glucose markers, yet they continue to experience cycle irregularity and ovulatory dysfunction. If the market continues focusing exclusively on blood sugar and weight management, an important consumer segment risks being overlooked.
4. Long-term ovarian health: The next growth category
Historically, fertility discussions focused on one question: Can ovulation be restored? But women today are delaying pregnancy, extending reproductive timelines, and paying greater attention to long-term reproductive health.
Meanwhile, oxidative stress, chronic inflammation, poor sleep, and metabolic burden quietly accumulate over time. As a result, long-term ovarian health is emerging as a major category opportunity – one focused not only on immediate fertility support, but on preserving ovarian resilience and reproductive longevity.
What comes after inositol? The next generation of PCOS supplements
The inositol era transformed PCOS supplements. Today, combinations of myo-inositol, D-chiro-inositol, methylfolate, vitamin D, and metabolic support ingredients dominate the market because they help improve insulin sensitivity and menstrual regularity.5
But consumers are increasingly asking more complicated questions:
- Why has my cycle improved while acne remains unchanged?
- Why do androgen symptoms persist despite stable weight?
- How do I support long-term hormonal and ovarian health – not just fertility?
These questions point toward the future of women’s endocrine balance.
Three ingredients worth watching in the next PMOS era
1. Urolithin A: Supporting ovarian resilience
As delayed childbearing becomes more common, preserving ovarian function may become just as important as restoring ovulation. Current metabolic interventions can improve follicular quality, but they do little to address long-term ovarian reserve dynamics.
This is where urolithin A becomes particularly interesting.
Emerging evidence suggests urolithin A may help reduce oxidative stress in ovarian granulosa cells, support steroid hormone synthesis, and promote healthier cellular function associated with ovarian aging.6 Research also suggests a role in supporting endogenous NAD+ production and cellular renewal – mechanisms increasingly linked to healthy aging.7
In practical terms, urolithin A is less about short-term symptom relief and more about long-term ovarian resilience. For women thinking five to ten years ahead, that distinction may matter increasingly.
2. S-equol: A new angle on hormonal regulation
Not all hormone-related problems stem from hormone quantity alone. Sometimes, the challenge lies in regulation. S-equol, a selective estrogen receptor beta (ERβ) modulator derived from soy metabolism, is gaining attention for its potential role in endocrine feedback and hormonal balance.
Its selective affinity for ERβ suggests the possibility of supporting hormonal signaling without excessive estrogenic stimulation. Research also indicates S-equol may bind dihydrotestosterone (DHT), potentially reducing androgen activity associated with acne, oily skin, and hair concerns.8
For women with relatively normal metabolic markers but persistent hormonal instability, S-equol may represent an important complementary approach to hormonal regulation and endocrine balance.
3. Fisetin: Optimizing the ovarian microenvironment
Increasingly, researchers are recognizing that ovarian function depends heavily on local biological conditions. Chronic inflammation, oxidative stress, and cellular dysfunction may create an environment that compromises follicular quality and ovarian performance over time.
Fisetin, widely studied for its senolytic and healthy-aging potential, has attracted attention for its role in cellular clean-up, inflammation management, and oxidative stress modulation.
Preclinical studies also suggest potential relevance to ovarian energy metabolic balance and androgen pathways, including the inhibition of testosterone conversion to DHT – an effect that may prove relevant for androgen-related hair concerns.9,10
Fisetin is unlikely to be a quick-fix ingredient. Its strength lies in supporting a healthier ovarian microenvironment and aligning with a broader shift toward long-term women’s metabolic and hormonal health.
A more integrated approach to women’s health
The shift from PCOS to PMOS is not just a naming update. It signals a transition from one-dimensional thinking to a more integrated understanding of women’s hormonal health, endocrine balance, ovarian health, and metabolic regulation.
The future will belong to brands asking a more strategic question: which PMOS problem are we actually solving?
At Bonerge, this perspective shapes the approach to women’s health innovation. Bonerge believes the future lies in integrated, lifecycle-oriented solutions that address metabolic support, hormonal regulation, ovarian resilience, and long-term endocrine wellbeing.
Through ingredients such as StanYouth® Urolithin A, EquoYouth® S-Equol, and BeFisetin® Fisetin, alongside complementary solutions including creatine, vitamin D, L-5-Methyltetrahydrofolate calcium, shatavari, black cohosh, and saffron extract, Bonerge is building a science-driven platform for women’s endocrine and metabolic health across different life stages.
Looking ahead, 2026 will mark an important milestone for Bonerge, as it initiates multiple human clinical studies focused on women’s health outcomes. Bonerge welcomes collaboration with brands and scientific teams to jointly participate in clinical research, validate emerging health solutions, and accelerate the translation of scientific insights into real-world applications.
References
- Teede, HJ.; et al. Global Name Change Consortium. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. 2026; 6;407(10545):2329-2339.
- Albardan, L.; et al. Role of Omega-3 Fatty Acids in Improving Metabolic Dysfunctions in Polycystic Ovary Syndrome. Nutrients. 2024;16(17):2961.
- Chen, X.; et al. Hypothalamic mechanisms of obesity-associated disturbance of hypothalamic-pituitary-ovarian axis. Trends Endocrinol Metab. 2022;33(3):206-217.
- Yildiz, BO.; et al. The adrenal and polycystic ovary syndrome. Rev Endocr Metab Disord. 2007;8(4):331-42.
- Bevilacqua, A.; et al. Physiological role and clinical utility of inositols in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2016;37:129-139.
- Li S, Tang, M.; et al. SIRT3 attenuates AGEs-induced senescence in human granulosa cells through enhancing mitophagy [J]. Cell biology and toxicology. 2026; 42(1): 20.
- Ghosh, N.; et al. Urolithin A augments angiogenic pathways in skeletal muscle by bolstering NAD+ and SIRT1. Sci Rep. 2020;10(1):20184.
- Xu, Y.; et al. Roles of estrogen and its receptors in polycystic ovary syndrome. Front Cell Dev Biol. 2024;12:1395331.
- Yang, Z.; et al. Flavonoid Fisetin Alleviates Ovarian Aging of Laying Chickens by Enhancing Antioxidant Capacity and Glucose Metabolic Homeostasis [J]. Antioxidants (Basel, Switzerland). 2024; 13(12).
- Hiipakka, R.A.; et al. Structure-activity relationships for inhibition of human 5alpha-reductases by polyphenols. Biochem Pharmacol. 2002;63(6):1165-76.
